Clinical Trials Directory

Trials / Unknown

UnknownNCT06317142

Glucose and Glycogen Dynamics in Prediabetes

Investigating Disturbances in Glucose and Glycogen Dynamics in Prediabetes

Status
Unknown
Phase
Study type
Observational
Enrollment
45 (estimated)
Sponsor
Maastricht University Medical Center · Academic / Other
Sex
All
Age
45 Years – 75 Years
Healthy volunteers
Accepted

Summary

The goal of this observational study is to investigate changes in nocturnal and postprandial glucose and glycogen metabolism in individuals with impaired fasting glucose and impaired glucose tolerance compared to healthy, non-diabetic, overweight participants (15 per group). In addition, it will be investigated if reducing gluconeogenesis, by using the challenge agent Acipimox, in people with prediabetes can increase glucose tolerance and fat oxidation by increased reliance on hepatic glycogen. The main questions this project aims to answer are: * whether there are differences in nocturnal glucose/glycogen metabolism in individuals with impaired fasting glucose, impaired glucose tolerance and healthy overweight controls. * whether there are differences in postprandial glucose/glycogen metabolism in individuals with impaired fasting glucose, impaired glucose tolerance and healthy overweight controls. Participants will visit the university for a screening visit and a visit with overnight stay for measurements of gluconeogenesis, glycogen, and substrate oxidation. A subgroup will receive \[18F\]-FDG to assess tissue-specific postprandial glucose uptake. Thereafter, 20 prediabetic individuals will follow a 4-day treatment with acipimox to decrease gluconeogenesis, followed by a second overnight visit with similar measurements as mentioned for the first visit.

Conditions

Interventions

TypeNameDescription
DRUGAcipimox 250 mg Oral CapsuleA subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.

Timeline

Start date
2024-02-20
Primary completion
2025-07-01
Completion
2025-07-01
First posted
2024-03-19
Last updated
2024-04-09

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06317142. Inclusion in this directory is not an endorsement.